ReviewClinical kidney journal2026
Single or multiple nutritional hormone receptor modulators for chronic kidney disease.
Review in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global rise in obesity and type 2 diabetes mellitus (T2DM) has contributed substantially to the increasing burden of chronic kidney disease (CKD), cardiovascular disease, and heart failure, highlighting the need for therapeutic strategies capable of addressing multiple components of the cardio-renal-metabolic axis. Incretin-based therapies have undergone an evolution from glucose-lowering agents to treatments with broad metabolic, cardiovascular, and renal effects. Glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated clinically meaningful reductions in cardiovascular events and have emerged as important therapies for kidney protection. Evidence from cardiovascular and kidney outcome trials, culminating in the FLOW study, has established semaglutide as a clinically relevant strategy for reducing kidney and cardiovascular risk in patients with T2DM and CKD. Beyond single-receptor agonism, the development of dual and triple incretin receptor agonists has expanded the therapeutic possibilities. Tirzepatide, a dual GLP-1/GIP receptor agonist, has demonstrated favourable kidney outcomes compared with dulaglutide, while early studies of the dual GLP-1/glucagon receptor agonist cotadutide suggest additional benefits on albuminuria and cardiorenal risk markers. Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, has shown promising effects on kidney-related parameters, although the mechanisms underlying observed increases in estimated glomerular filtration rate remain uncertain. Accumulating evidence suggests that incretin-based therapies may exert renoprotective effects through pathways extending beyond glycaemic control and weight reduction, including improvements in endothelial function, microvascular integrity, inflammation, fibrosis, and renal haemodynamics. Nevertheless, important questions remain regarding the mechanisms of kidney protection, the interpretation of kidney function changes in the setting of substantial weight loss, and the long-term renal benefits of multi-receptor modulators. Ongoing mechanistic studies and dedicated outcome trials will further define the role of incretin biology in the prevention and treatment of CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.